559

PATIENT CHARACTERISTICS ARE ASSOCIATED WITH RESPONSE TO ERCP FOR SPHINCTER OF ODDI DISORDERS, BUT PHYSICIAN-DEFINED SOD SUBTYPES ARE NOT: THE RESPOND LONGITUDINAL COHORT STUDY

Date
May 19, 2024

Background: Sphincter of Oddi Disorders (SOD) describes a contentious and heterogeneous diagnosis in patients whose abdominal pain, idiopathic acute pancreatitis (AP), or both may derive from a spastic or stenotic sphincter. Traditionally, SOD is categorized by ≥1 physician-defined factor: dilated bile duct ≥12mm, elevated liver (>2x ULN) or pancreas (>3x ULN) labs, and idiopathic AP. With broader use of noninvasive imaging and evidence suggesting no benefit of ERCP for abdominal pain alone, the Results of Ercp for Sphincter of Oddi Disorders (RESPOnD) study aimed to measure the benefit of ERCP in this controversial context.

Methods: RESPOnD was a prospective cohort conducted at 14 U.S. centers. Patients undergoing first-time ERCP with sphincterotomy for suspected SOD (biliary, pancreatic, or mixed type) were eligible. After informed consent, patients completed a baseline assessment including validated questionnaires to characterize pain, pain-related disability, and potential confounders such as somatization, mood disorder, and recent opioid use. At 12 months after ERCP, the primary outcome was defined as the composite of being “improved” or “much improved” by Patient Global Impression of Change, no new or increased opioids, and no repeat intervention. Missing data were addressed using a hierarchal, multiple imputation scheme.

Results: Of 316 patients screened, 216 were enrolled and 3 excluded due to inability to complete ERCP (2) or missing consent (1). Most (190/213, 89%) subjects presented with ≥1 physician-defined characteristics of SOD (duct dilation, abnormal pancreatobiliary lab, and/or AP history). Of 213 patients, an average of 122 (57.4% [95%CI 50.4-64.4]) met the multiply imputed primary outcome for success; 23/213 (10.8%) developed post-ERCP pancreatitis. Outcomes were similar across Rome III subtypes (table 1). Recent opioid use, irritable bowel syndrome history, somatization, depression, anxiety, and low physical or mental health were associated univariately with lower success (table 2). AP > 30 days after index ERCP (or follow-up ERCP, if performed) developed in 40/213 (18.8%) at a median of 6 months after index ERCP and was more likely if there was a prior history of AP (31.8 vs. 4.9%, p<0.0001).

Conclusion: Patient characteristics are associated with response to ERCP treatment whereas traditional physician-defined characteristics such as duct dilation are not. The overall response rate (57%) is numerically higher than in the EPISOD study (abdominal pain alone) but does not rule out a substantial placebo response. AP occurs frequently after sphincterotomy, especially if there was a history of AP prior to enrollment, suggesting no benefit. Additional examination needs to be done in a multivariable setting and future trials should focus on measuring the treatment effect in patients with the most favorable baseline characteristics.
<b>Table 1. Physician defined characteristics of SOD and response to ERCP treatment</b>

Table 1. Physician defined characteristics of SOD and response to ERCP treatment

<b>Table 2. Patient characteristics and response to ERCP treatment for suspected SOD</b>

Table 2. Patient characteristics and response to ERCP treatment for suspected SOD

Presenter

Speaker Image for Gregory Cote
Oregon Health & Science University

Speakers

Speaker Image for Badih Elmunzer
Medical University of South Carolina
Speaker Image for Richard Kwon
University of Michigan
Speaker Image for Field Willingham
Emory University
Speaker Image for Sachin Wani
University of Colorado
Speaker Image for Vladimir Kushnir
Washington University School of Medicine
Speaker Image for Amitabh Chak
Univ Hospital of Cleveland
Speaker Image for Vikesh Singh
Johns Hopkins University School of Medicine
Speaker Image for Georgios Papachristou
Ohio State University Wexner Medical Center
Speaker Image for Shyam Varadarajulu
Orlando Health Digestive Health Institute

Tracks

Related Products

Thumbnail for MACHINE LEARNING BASED DIAGNOSIS OF MALIGNANCY DURING BILE DUCT STRICTURE EVALUATION USING CHOLANGIOSCOPY
MACHINE LEARNING BASED DIAGNOSIS OF MALIGNANCY DURING BILE DUCT STRICTURE EVALUATION USING CHOLANGIOSCOPY
Introduction: Adenoma per colonoscopy (APC) has recently been proposed as a quality measure for colonoscopy. We evaluated the impact of a novel AI system, compared to standard HD colonoscopy, for APC measurement…
Thumbnail for PRE TPIAT OPIOID USE AND SMOKING STATUS WERE INDEPENDENTLY ASSOCIATED WITH HIGHER ODDS OF DAILY OPIOID USE AT 1 YEAR POST TPIAT-RESULTS FROM THE PROSPECTIVE OBSERVATIONAL STUDY OF TPIAT (POST) COHORT
PRE TPIAT OPIOID USE AND SMOKING STATUS WERE INDEPENDENTLY ASSOCIATED WITH HIGHER ODDS OF DAILY OPIOID USE AT 1 YEAR POST TPIAT-RESULTS FROM THE PROSPECTIVE OBSERVATIONAL STUDY OF TPIAT (POST) COHORT
TPIAT is considered in chronic pancreatitis (CP) and recurrent acute pancreatitis (RAP) to mitigate pain and improve quality of life (QOL) when medical and endoscopic therapy fail…
Thumbnail for LOW INCIDENCE OF RECURRENT NEOPLASTIC BARRETT’S ESOPHAGUS (BE) AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY (EET): LONG-TERM OUTCOMES FROM A MULTICENTER PROSPECTIVE COHORT STUDY
LOW INCIDENCE OF RECURRENT NEOPLASTIC BARRETT’S ESOPHAGUS (BE) AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY (EET): LONG-TERM OUTCOMES FROM A MULTICENTER PROSPECTIVE COHORT STUDY
INTRODUCTION: EET is endorsed by guidelines for treatment of BE-related neoplasia patients. Few studies describe long-term durability outcomes in BE patients who achieve complete eradication of intestinal metaplasia (CE-IM) following EET…
Thumbnail for DEVELOPMENT AND VALIDATION OF A MACHINE LEARNING (ML) BASED DECISION-MAKING TOOL TO DETERMINE RISK AND TIMING OF RECURRENCE OF BARRETT’S ESOPHAGUS (BE) NEOPLASIA AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY (EET)
DEVELOPMENT AND VALIDATION OF A MACHINE LEARNING (ML) BASED DECISION-MAKING TOOL TO DETERMINE RISK AND TIMING OF RECURRENCE OF BARRETT’S ESOPHAGUS (BE) NEOPLASIA AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY (EET)
Recent studies have described the durability of EET for BE-related neoplasia and the risk of neoplastic recurrence after achieving complete eradication of intestinal metaplasia (CE-IM). Current guidelines for endoscopic surveillance intervals post-EET are based on limited evidence…